CAMBRIDGE, MASS. & OSAKA, JAPAN--( / ) March 05, 2020 -- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients. SARS-CoV-2 is the virus that causes COVID-19.
Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19. As a leader in plasma-derived therapies with more than 75 years of experience in the development of plasma-derived products, Takeda has the expertise to research, develop, and manufacture a potential anti-SARS-CoV-2 polyclonal H-IG, which Takeda is referring to as TAK-888.
“As a company dedicated to the health and well-being of people around the world, we will do all that we can to address the novel coronavirus threat,” said Dr. Rajeev Venkayya, President of Takeda’s Vaccine Business Unit and co-lead of the company’s COVID-19 response team. “We have identified relevant assets and capabilities across the company and are hopeful that we can expand the treatment options for patients with COVID-19 and the providers caring for them.”
Takeda is currently in discussions with multiple national health and regulatory agencies and health care partners in the US, Asia, and Europe to expeditiously move the research into TAK-888 forward. This requires access to source plasma from people who have successfully recovered from COVID-19 or who have been vaccinated, once a vaccine is developed. These convalescent donors have developed antibodies to the virus that could potentially mitigate severity of illness in COVID-19 patients and possibly prevent it.
H-IG works by concentrating the pathogen-specific antibodies from plasma collected from recovered patients or vaccinated donors in the future. By transferring the antibodies to a new patient, it may help that person’s immune system respond to the infection and increase their chance of recovery. Because the plasma needed for TAK-888 is unlikely to come from current plasma donors, Takeda will initially produce the therapy in a segregated area within its manufacturing facility in Georgia, and development and production of it should not negatively impact Takeda’s ability to produce its other plasma-derived therapies.
“Plasma-derived therapies are critical, life-saving medicines that thousands of people with rare and complex diseases rely on every day around the world,” said Dr. Chris Morabito, Takeda’s Head of Research and Development, Plasma-Derived Therapies Business Unit. “Our heritage, combined with our scale, expertise and capabilities, uniquely position Takeda to realize the potential of plasma-derived therapies, such as TAK-888.”
In addition, Takeda is exploring whether select marketed therapies and molecules in its drug library could be viable candidates for the effective treatment of COVID-19. These efforts are at an early stage but being given a high priority within the company.
An internal working group of in-house experts in public health, vaccines, plasma-derived therapies, and R&D will continue to seek opportunities to leverage our expertise and extensive network of global partners to address COVID-19. COVID-19 is the disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), which can cause pneumonia and has resulted in more than 3,000 deaths globally since its recent discovery. To date, there are no approved vaccines or therapies to prevent or treat COVID-19.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit
About Plasma-Derived Therapies
Plasma-derived therapies are essential for treating patients with a variety of rare, life-threatening, complex and genetic diseases for which there are few or no other treatment options. Plasma is the clear, straw-colored liquid portion of blood that remains after red blood cells, white blood cells, and platelets are removed. Plasma has multiple components with different clinical uses. ?Plasma products have existed for ~ 80 years, and industry-wide research is underway to assess the larger potential therapeutic value of plasma in new diseases.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information?D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SEOUL, SOUTH KOREA--( / ) April 02, 2014 -- Family owned, Austrian company CROMA-PHARMA 황산면홀덤대회 vporn announced today 황산면홀덤대회 the signing of a 10 year comprehensive and important distribution agreement with Hugel Inc. of Korea. Hugel Inc. is the 스포츠중계비비TV SEOUL,producer 호박알바 TUBXPORN of anti-aging and Botulinum Toxin products in South Korea and Asia. 황산면홀덤대회 야동파일
At the signing, Andreas Prinz, Managing Director and Owner of CROMA-PHARMA said: ?CROMA-PHARMA is always committed to bringing the most advanced anti-aging 황산면홀덤대회 연금복권추천 and medical products to patients and doctors alike. With this agreement CROMA-PHARMA will add the 황산면홀덤대회 most sophisticated Botulinum Toxin products to its well established range of Filler Products sold by the brand-name 호박알바 of Princess®. These Princess® Fillers (Rich, Volume and Filler), produced by CROMA-PHARMA itself, are all based on 호박알바 연금복권당첨번호조회 Hyaluronic Acid. Intensive research and experience 호박알바 오랄 made 일본동영상 Atthe leading European producer and specialist of Hyaluronic Acid-based products. These new Botulinum Toxin-based products will perfectly complement our existing portfolio, meeting the demands of both aesthetic doctors and customers as well“.
Dr. 호박알바 로또필터 Kyeong-Yeop Moon, C.E.O of Hugel Inc. said in a statement: Since 2001 Hugel has focused its research on only one area in order to develop the best possible anti-aging products available anywhere. We do our 호박알바 야동망고 very best to develop innovative, top-quality 한아시아 Dr.that completely satisfy our customers. With CROMA-PHARMA, we have found 황산면홀덤대회 야오리 the perfect partner to distribute and market our products everywhere outside Asia.
CROMA-PHARMA will become the exclusive Distribution Partner and will be responsible for conducting the required clinical trials and studies. CROMA-PHARMA expects to 넷마블포커현금 CROMA-PHARMAan estimated two-digit million Euro amount for conducting these studies. Following the final approval of FDA, EMA and 호박알바 야야방 other authorities, CROMA-PHARMA will then market the 호박알바 노리터 new 황산면홀덤대회 유미닷컴 products 황산면홀덤대회 AVSEE in Europe, North America and Oceania markets. CROMA-PHARMA will promote the new products 대수홈케어 CROMA-PHARMAtheir own brand. Products shall enter the markets in 2018. Forecast of sales 황산면홀덤대회 OKBOY until 호박알바 오빠나빠 2021 estimate returns of more than 100 million Euro in this dynamically growing market.
CROMA-PHARMA´s constant search for 호박알바 AV타운 new trends and 치마쩍벌 CROMA-PHARMA´sinnovations 황산면홀덤대회 will 호박알바 황산면홀덤대회 bring more 블랙티비TV CROMA-PHARMA´sto its well-established 호박알바 599넷 product-portfolio 블랙티비TV CROMA-PHARMA´s황산면홀덤대회 소리바다 2014.
Botulinum toxin is a protein 야동사진 Botulinumand neurotoxin () produced by 스포츠토토토토분석방 Botulinum호박알바 bacterium Clostridium botulinum (). 황산면홀덤대회 무료로또번호추출기 Three forms of botulinum 황산면홀덤대회 toxin type A and one form of 황산면홀덤대회 햄스터 botulinum toxin type B are available commercially for various cosmetic and medical procedures.
About 황산면홀덤대회 tubev 황금성솔루션 About호박알바
황금성솔루션 CROMA-PHARMAis a family owned, internationally orientated pharmaceutical company, based in Korneuburg, Austria. CROMA-PHARMA´s areas of activity are orthopedics, ophthalmology, 호박알바 포르노HD dermatology and 호박알바 비그 contract manufacturing. CROMA-PHARMA is dedicated to improving people’s quality of life through innovative, consistently simple and 황산면홀덤대회 로또규칙 effective health solutions.
Constant focus 호박알바 로또번호조회 on research & 황산면홀덤대회 pornhub development and 호박알바 mustjav thrive to produce only the best and most innovative products 황산면홀덤대회 javbraze enables CROMA-PHARMA to master the challenges 호박알바 로또번호정리 of 황금성솔루션 Constanthealth care.
비아그라약효 Forfurther 황산면홀덤대회 오피일번가 information on 호박알바 CROMA-PHARMA please visit
About 일회용마사지젤판매쇼핑몰 About호박알바 오피걸스 황산면홀덤대회 오피걸스 Inc.
Hugel Inc. is a market leader 호박알바 텐프로미 in the South Korean aesthetic market with a portfolio of products that includes cosmeceuticals, neurotoxins and dermal fillers. The company has enjoyed rapid growth in recent years and is focused on developing or acquiring innovative new products and technologies in 항문섹스자극적인거 Hugelpharmaceutical, 황산면홀덤대회 cosmetic, and medical device 호박알바 fields that complement its existing portfolio. Hugel Inc. recently expanded its manufacturing capabilities with the construction of 조이앤조이 Hugelnew production facility. 호박알바 For further information on Hugel Inc please visitKorea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.